Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

4Total
Not Applicable (1)
P 1 (2)
P 2 (1)

Trial Status

Recruiting4
Not Yet Recruiting1

Clinical Trials (5)

Showing 5 of 5 trials
NCT06974110Phase 1Recruiting

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

NCT07374809Not ApplicableNot Yet Recruiting

IMMUNOTHERAPY EFFICACY TARGETING ENDOMETRIAL CANCER

NCT05086692Phase 1Recruiting

A Beta-only IL-2 ImmunoTherapY Study

NCT06580574Phase 2Recruiting

Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers

NCT06004713RecruitingPrimary

Registry Study in MSI/dMMR Solid Tumors

Showing all 5 trials

Research Network

Activity Timeline